CAS registry number (Chemical Abstracts Service)
Antidiabetic agent: Incretin-mimetic, glucagon-like peptide-1 (GLP-1) agonist
des-38-proline-exendine-4 (Heloderma suspectum)-(1-39)-peptidylpenta-L-lysyl-L-lysinamide (WHO )
- Lixisenatidum (Latin)
- Lixisenatid (German)
- Lixisénatide (French)
- Lixisenatida (Spanish)
- Lixisenatide (OS: JAN)
- AQVE-10010 (IS)
- AVE 0010 (IS)
- UNII-74O62BB01U (IS)
- ZP 10 (IS)
Sanofi, Dominican Republic; Sanofi, United Kingdom; Sanofi, Guatemala; Sanofi, Ireland; Sanofi, Japan; Sanofi, Panama; Sanofi, Sweden; Sanofi Aventis, Spain; Sanofi Oy, Finland; Sanofi-Aventis, Austria; Sanofi-Aventis, Bosnia & Herzegowina; Sanofi-Aventis, Belgium; Sanofi-Aventis, Costa Rica; Sanofi-Aventis, Denmark; Sanofi-Aventis, Honduras; Sanofi-Aventis, Hungary; Sanofi-Aventis, Iceland; Sanofi-Aventis, Italy; Sanofi-Aventis, Latvia; Sanofi-Aventis, Mexico; Sanofi-Aventis, Nicaragua; Sanofi-Aventis, Norway; Sanofi-Aventis, Poland; Sanofi-Aventis, Romania; Sanofi-Aventis, Slovakia; Sanofi-Aventis, El Salvador; Sanofi-Aventis Groupe, Slovenia; Sanofi-Aventis, Hong Kong
|JAN||Japanese Accepted Name|
|Rec.INN||Recommended International Nonproprietary Name (World Health Organization)|
Further information on drug naming conventions: International Nonproprietary Names.
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.